OR WAIT null SECS
Recipharm Inhalation Solutions is an integrated service for inhalation products.
Recipharm, a contract development and manufacturing organization (CDMO), has launched its end-to-end inhalation offering to provide customers with a fully integrated service from early-stage development through to commercial manufacturing, the company announced in a May 7, 2019 press release. Recipharm Inhalation Solutions offers pharmaceutical companies a seamless outsourcing service for inhalation products, including metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nasal sprays.
The offering follows the acquisition of Sanofi’s inhalation manufacturing business in Holmes Chapel, UK in June 2018, which has specialized in the manufacture of inhalation drug products for more than 40 years. The facility is supported by Recipharm’s inhalation development expertise in Research Triangle Park, NC, US.
“Treatments for respiratory conditions are in high demand, making inhalation products a key growth area for our business,” said Shabbir Mostafa, global key account director for inhalations at Recipharm. “In addition to respiratory diseases, they are now being explored as alternative delivery routes to improve bioavailability and lower the risk of adverse effects, in treating for instance central nervous system conditions. This is making inhalation an interesting area for drug developers.”
Recipharm Inhalation Solutions includes dedicated analytical services for inhalation products, including comprehensive extractable and leachable expertise. A dedicated pilot facility composed of several suites that can replicate commercial processes also assists with the seamless transfer of projects from small- to large-scale production. In addition, Recipharm has the technical ability to work with different devices, combinations, APIs, and suspension formulations.